Abstract
The purpose of this review is to determine the state of the art of the mode of action and potential applications of fluorescence photobiomodulation in veterinary medicine. After a summary of the assets that have led the translation of such light-based therapies from bench side into clinical use, recent advances in canine dermatology using this brand-new approach are presented, and future scenarios where this type of care may provide benefits over the current standard care are highlighted.
Highlights
These samples were assessed by immunohistochemistry considering the following parameters: epidermal growth factor (EGF), fibroblast growth factors (FGFs), transforming growth factor beta (TGF-β), tumor necrosis factor alpha (TNF-α), collagen (Coll) I and inhibition of specific signaling pathways; (III), Ki67, factor VIII (FVIII), and decorin (DCN)
It is possible to hypothesize that further research is needed prior to having a final device for the application of Fluorescent (photo) biomodulation (FBM) in canine otitis, the results presented in the abovementioned study highlight a beneficial anti-inflammatory and antiseptic effect of the treatment in this field [46], possibly supporting the healing process without burden on owner compliance
The studies described in this literature review are the evidence that PBM can exhibit its aptitudes in veterinary medicine
Summary
(III) generally reduced risk of interference with other treatment modalities, prevention of systemic side effects, and very precise targeting of specific structures by exploiting their different light-absorbing properties [6] For such reasons, the development and application of new therapeutic strategies in canine dermatology has attracted the interest of both researchers and trading companies. [24] PBM directly activates endogenous chromophores including cytochrome c oxidase [25], flavins [26], and opsins [27] It can modulate inflammation: both in vitro and in vivo studies have demonstrated the anti-inflammatory action of red (610–760 nm) light through the modulation of interleukin (IL)-1α and -β, IL-6, IL-17, and tissue necrosis factor (TNF)-α [28,29]. Inflammation may be modulated through matrix proteins such as matrix metalloproteinases (MMPs) and their tissue inhibitors [31]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
